City Therapeutics announces first patient dosed in City-Rbp4 Phase 1 trial
City Therapeutics dosed the first participant in a Phase 1 clinical trial of CITY-RBP4, targeting Stargardt disease. The trial aims to evaluate safety, tolerability, and pharmacodynamics with initial data expected in mid-2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed